Vectors for cancer gene therapy

Cancer and Metastasis Reviews

Volumn 15, Issue 3, 1996, Pages 385-401

  Zhang, J ^b   Russell, S J ^a  

^a MEDICAL RESEARCH COUNCIL   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

cancer; gene therapy; non viral vectors; replicating vectors; viral vectors

Indexed keywords

CANCER VACCINE; VIRUS VECTOR;

ANGIOGENESIS; CANCER; GENE THERAPY; HEMATOPOIETIC STEM CELL; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE;

EID: 0029803727     PISSN: 01677659     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF00046349     Document Type: Review

References (110)

1. Hawkins RE, Winter G, Stevenson FK, Russell SJ: A genetic approach to anti-idiotype immunisation. J Immunother 14: 237-278, 1993
2. Ali M, Lemoine NR, Ring CJA: The use of DNA viruses as vectors for gene therapy. Gene Ther 1: 367-384, 1994
3. Crystal RG: Transfer of genes to humans: Early lessons and obstacles to success. Science 270: 404-410, 1995
4. Efstathiou S, Minson AC: Herpes virus-based vectors. Br Med Bull 51 (1): 45-55, 1995
5. Schofield JP, Caskey CT: Non-viral approaches to gene therapy. Br Med Bull 51 (1): 56-71, 1995
6. Vile RG, Russell SJ: Retroviruses as vectors. Br Med Bull 51 (1): 12-30, 1995
7. Kremer EJ, Perricaudet M: Adenovirus and adeno-associated virus mediated gene transfer. Br Med Bull 51 (1): 31-34, 1995
8. Berglund P, Tubulekas I, Liljestrom P: Alphaviruses as vectors for gene delivery. Trends Biotech 14: 130-134, 1996
9. Kobayashi H: The biological modification of tumor cells as a means of inducing their regression: An overview. J Biol Resp Mod 5: 1-11, 1986
10. Heicappell R, Schirrmacher V, Von Hoegen P, Ahlert T, Appelhans B: Prevention of metastatic spread by postoperative immunotherapy with virally modified autologous tumor cells. I. Parameters for optimal therapeutic effects. Int J Cancer 37: 569-577, 1986
11. Brissinck J, Zhang J, Shaw M, Russell SJ: Current clinical trials using gene therapy for cancer. In: Vile R (ed) Cancer, Prospects for Gene Therapy. Springer-Verlag London Ltd., 1996 (in press)
12. Vile RG, Hart IR: In vitro and in vivo targeting of gene expression to melanoma cells. Cancer Res 53: 962-967, 1993
13. Vile RG, Hart IR: Use of tissue-specific expression of the herpes simplex virus thymidine kinase gene to inhibit growth of established murine melanomas following direct intratumoral injection of DNA. Cancer Res 53: 3860-3864, 1993
14. Vile RG, Diaz RM, Mitchell S, Tuszyanski A, Russell SJ: Tissue-specific gene expression from Mo-MLV retroviral vectors with hybrid LTRs containing the murine tyrosinase enhancer/promoter. Virology 214 (1): 307-313, 1995
15. Kaneko S, Hallenbeck P, Kotani T, Nakabayashi H, McGarrity G, Tamaoki T, Anderson WF, Chiang YL: Adenovirus-mediated gene therapy of hepatocellular carcinoma using cancer-specific gene expression. Cancer Res 55 (22): 5283-5287, 1995
16. Chen L, Chen D, Manome Y, Dong Y, Fine HA, Kufe DW: Breast cancer selective gene expression and therapy mediated by recombinant adenoviruses containing the DF3/ MUC1 promoter. J Clin Invest 96 (6): 2775-2782, 1995
17. Schrewe H, Thompson J, Bona M, Hefta L, Maruya A, Hassauer M, Shively J, Heist S, Zimmamann W: Cloning of the complete gene for carcinoembryonic antigen: analysis of its promoter indicates a region conveying cell type-specific expression. Mol Cell Biol 10 (6): 2738-2748, 1990
18. Richards CA, Austin EA, Huber BE: Transcriptional regulatory sequences of carcinoembryonic antigen: Identification and use with cytosine deaminase for tumor-specific gene therapy. Hum Gene Ther 6: 881-893, 1995
19. Lemoine NR, Jain S, Silvestre F: Amplification and overexpression of the EGF receptor and c-erbB-2 oncogenes in human stomach cancer. Br J Cancer 64: 74-83, 1991
20. Hall PA, Hughes CM, Staddon SL, Richman PA, Gullick WJ, Lemoine NR: The c-erbB-2 proto-oncogene in human pancreatic cancer. J Pathol 161: 195-200, 1990
21. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235: 177-182, 1987
22. Harris JD, Gutierrez AA, Hurst HC, Sikora K, Lemoine NR: Gene therapy for cancer using tumour-specific prodrug activation. Gene Ther 1: 170-175, 1994
23. Salmons B, Saller RM, Baumann JG, Gunzburg WH: Construction of retroviral vectors for targeted delivery and expression of therapeutic genes. Leukemia 9 (Suppl): S53-S60, 1995
24. Friedman JM, Babiss LE, Clayton DF, Darnell Jr JE: Cellular promoters incorporated into the adenovirus genome: Cell specificity of albumin and immunoglobulin expression. Mol Cell Biol 6: 3791-3797, 1986
25. Salmons B, Gunzburg WH: Targeting of retroviral vectors for gene therapy. Hum Gene Ther 4: 129-141, 1993
26. Garver Jr RI, Goldsmith KT, Rudo B, Hu P-C, Sorscher EJ: Strategy for achieving selective killing of carcinomas. Gene Ther 1: 46-50, 1994
27. Cooper NR, Jensen FC, Raymond MW, Oldstone MBA: Lysis of RNA tumor viruses by human serum: direct antibody-independent triggering of the classical complement pathway. J Exp Med 144: 970-984, 1976
28. Welsh RM, Cooper NR, Jensen FC, Oldstone MBA: Human serum lyses RNA tumor viruses. Nature 257: 612-614, 1975
29. Welsh RM, Cooper NR, Jensen FC, Oldstone MBA: Inactivation and lysis of oncornaviruses by human scrum. Virology 74: 432-440, 1976
30. Takeuchi Y, Porter CD, Strahan KM, Reece AF, Gustafsson K, Cosset F-L, Weiss RA, Collins MKL: Sensitization of cells and retroviruses to human serum by )α1-3) galactosyltransferase. Nature 379: 85-88, 1996
31. Cosset F-L, Takeuchi Y, Battini J-L, Weiss RA, Collins MKL: High-titer packaging cells producing recombinant retroviruses resistant to human serum. J Virol 69 (12): 7430-7436, 1995
32. Rother RP, Squinto SP, Mason JM, Rollins SA: Protection of retroviral vector particles in human blood through complement inhibition. Hum Gene Ther 6: 429-435, 1995
33. Takeuchi Y, Cosset F-LC, Lachmann PJ, Okada H, Weiss RA, Collins MKL: Type C retrovirus inactivation by human complement is determined by both the viral genome and the producer cell. J Virol 68 (12): 8001-8007, 1994
34. Pensiero MN, Wysocki CA, Nader K, Kikuchi GE: Development of amphotropic murine retrovirus vectors resistant to inactivation by human serum. Gene Ther 1996 (in press)
35. Collins T, Williams A, Johnston GI, Kim J, Eddy R, Shows T, Gimbrone Jr MA, Bevilacqua MP, Structure and chromosomal location of the gene for endothelial-leukocyte adhesion molecule I. J Biol Chem 266 (4): 2466-2473, 1991
36. De Vries C, Escobedo JA, Ueno H, Houck K, Ferrara N, Williams LT: The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science 255: 989-991, 1992
37. Michael SI, Huang CH, Romer MU, Wagner E, Hu P, Curiel DT: Binding-incompetent adenovirus facilitates molecular conjugate-mediated gene transfer by the receptor-mediated endocytosis pathway. J Biol Chem 268 (10): 6866-6869, 1993
38. Michael SI, Curiel DT: Strategies to achieve targeted gene delivery via the receptor-mediated endocytosis pathway. Gene Ther (1): 223-232, 1994
39. Cristiano R, Smith LC, Woo SLC: Hepatic gene therapy: Adenovirus enhancement of receptor-mediated gene delivery and expression in primary hepatocytes. Proc Natl Acad Sci USA 90: 2122-2126, 1993
40. Albritton LM, Woo J-K, Tseng L, Cunningham JM: Envelope-binding domain in the cationic amino acid transporter determines the host range of ecotropic murine retroviruses. J Virol 2091-2096, 1993
41. Albritton LM, Tseng L, Scadden D, Cunningham JM: A putative murine ecotropic retrovirus receptor gene encodes a multiple membrane-spanning protein and confers susceptibility to virus infection. Cell 57: 659-666, 1989
42. Kavanaugh MP, Miller DG, Zhang W-B, Law W, Kozak SL, Kabat D, Miller AD: Cell-surface receptor for gibbon ape leukemiavirus and amphotropic murine retrovirus are inducible sodium-dependent phosphate symporters. Proc Natl Acad Sci USA 91: 7071-7075, 1994
43. Van Zeijl M, Johann SV, Closs E, Cunningham J, Eddy R, Shows TB, O'Hara B: A human amphotropic retrovirus receptor in a second member of the gibbon ape leukemia virus receptor family. Proc Natl Acad Sci USA 91: 1168-1172, 1994
44. Miller DG, Edwards RH, Miller AD: Cloning of the cellular receptor for amphotropic murine retroviruses reveals homology to that for gibbon ape leukemia virus. Proc Natl Acad Sci USA 91: 78-82, 1994
45. Russell SJ, Hawkins RE, Winter G: Retroviral vectors displaying functional antibody fragments. Nucl Acids Res 21: 1081-1085, 1993
46. Cosset FL: Retroviral retargeting by envelopes expressing an N-terminal binding domain. J Virol 69: 6314-6322, 1995
47. Valsesia-Wittmann S, Drynda A, Deleage G, Aumailley M, Heard J-M, Danos O, Verdier G, Cosset F-L: Modifications in the binding domain of avian retrovirus envelope protein to redirect the host range of retroviral vectors. J Virol 68: 4609-4619, 1994
48. Kasahara N, Dozy AM, Kan YW: Tissue-specific targeting of retroviral vectors through ligand-receptor interactions. Science 266: 1373-1376, 1994
49. Chu THT, Dornburg R: Retroviral vector particles displaying the antigen-binding site of an antibody enable cell-type-specific gene transfer. J Virol 69: 2659-2663, 1995
50. Somia NV, Zoppe M, Verma IM: Generationn of targeted retroviral vectors by using single-chain variable fragment: An approach to in vivo gene delivery. Proc Natl Acad Sci USA 92: 7570-7574, 1995
51. Nilson BHK, Morling FJ, Cosset F-L, Russell SJ: Targeting of retroviral vectors through protease-substrate interactions. Gene Ther 1996 (in press)
52. Michael SI, Hong JS, Curiel DT, Engler JA: Addition of a short peptide ligand to the adenovirus fiber protein. Gene Ther 2: 660-668, 1995
53. Wickham TJ, Carrion ME, Kovesdi I: Targeting of adenovirus penton base to new receptors through replacement of its RGD motif with other receptor-specific peptide. Hum Gene Ther 2: 750-756, 1995
54. Roe TY, Reynods TC, Yu G, Brown PO: Integration of murine leukemia virus DNA depends on mitosis. EMBO J 12 (5): 2099-2108, 1993
55. Gross G, Eshhar Z: Endowing T cells with antibody specificity using chimeric Tcell reporters FASEB J 6 (15): 3370-3378, 1992
56. Rosenberg SA: The immunotherapy and gene therapy of cancer. J Clin Oncol 10 (2): 180-199, 1992
57. Mecsas J, Sugden B: Replication of plasmids derived from bovine papilloma virus type 1 and Epstein-Barr virus in cells in culture. Annu Rev Cell Biol 3: 87-108, 1987
58. Ohe Y, Zhao DY, Saijo N, Podack ER: Construction of a novel bovine papillomavirus vector without detectable transforming activity suitable for gene transfer. Hum Gene Ther 6: 325-333, 1995
59. Piirsoo M, Ustav E, Mandel T, Stenlund A, Ustav M: Cis and trans requirements for stable episomal maintenance of the BPV-1 replicator. EMBO J 15 (1): 1-11, 1996
60. Gopalakrishnan V, Khan SA: El protein of human papillomavirus type la is sufficient for initiation of viral DNA replication. Proc Natl Acad Sci USA 91 (20): 9597-9601, 1994
61. Hwang ES, Naeger LK, DiMaio D: Activation of the endogenous p53 growth inhibitory pathway in HeLa cervical carcinoma cells by expression of the bovine papillomavirus E2 gene. Oncogene 12 (4): 795-803, 1996
62. Dowhanick JJ, McBride AA, Howley PM: Suppression of cellular proliferation by the papillomavirus E2 protein. J Virol 69 (12): 7791-7799, 1995
63. Van de Pol SB, Howley PM: Negative regulation of bovine papillomavirus E5, E6, and E7 oncogenes by the viral E1 and E2 genes. J Virol 69 (1): 395-402, 1995
64. Lutfalla G, Armbruster L, Dequin S, Bertolotti R: Construction of an EBNA-producing line of well differentiated human hepatoma cells and of appropriate Epstein-Barr virus based shuttle vectors. Gene 76: 27-39, 1989
65. Hambor JE, Hauer CA, Shu H-K, Groger RK, Kaplan DR, Tykocinski ML: Use of an Epstein-Barr virus episomal replicon for anti-sense RNA-mediated gene inhibition in a human cytotoxic T-cell clone. Proc Natl Acad Sci USA 85: 4010-4014, 1988
66. Yates JL, Warren N, Sugden B: Stable replication of plasmids derived from Epstein-Barr virus in various mammalian cells. Nature 313: 812-815, 1985
67. Rosenberg SA: Gene therapy of patients with advanced cancer using tumor infiltrating lymphocytes transduced with the gene coding for tumor necrosis factor. Hum Gene Ther 1: 441-480, 1990
68. Chatterjee S, Johnson PR, Wong Jr KK: Dual-target inhibition of HIV-1 by means of an adeno-associated virus antisense vector. Science 258: 1485-1488, 1992
69. Muro-Cacho CA, Samulski RJ, Kaplan D: Gene transfer in human lymphocytes using a vector based on adeno-associated virus. J Immunother 11: 231-237, 1992
70. Russell SJ: Replicating vectors for gene therapy of cancer: Risks, limitations and prospects. Eur J Cancer 30A (8): 1165-1171, 1994
71. Podsacoff G, Wang KK, Chatterjee S: Efficient gene transfer into non-dividing cells by AAV based vectors. J Virol 68: 5656-5666, 1994
72. Goodman S, Xiao X, Donahue RE, Moulton A, Miller J, Walsh C, Young NS, Samulski RJ, Nienhuis AW: Recombinant adeno-associated virus-mediated gene transfer into hematopoietic progenitor cells. Blood 84 (5): 1492-1500, 1994
73. Kaplitt MG, Leone P, Samulski RJ, Xiao X, Pfaff DW, O'Malley KL, During MJ: Long-term gene expression and phenotypic correction using adeno-associated virus vectors in the mammalian brain. Nature Gen 8: 148-154, 1994
74. Poznansky M, Lever A, Bergeron L, Haseltine W, Sodroski J: Gene transfer into human lymphocytes by a defective human immunodefiency virus type 1 vector. J Virol 65: 532-536, 1991
75. Shimada T, Fujii H, Mitsuya H, Nienhuis AW: Targeted and highly efficient gene transfer into CD4+ cells by a recombinant immunodefiency virus retroviral vector. J Clin Invest 88: 1043-1047, 1991
76. Russell DW, Miller AD: Foamy virus vectors. J Virol 70 (1): 217-222, 1996
77. Lewis P, Hensel M, Emerman M: Human immunodeficiency virus infection of cells arrested in the cell cycle. EMBO J 11 (8): 3053-3058, 1992
78. Li G, Simm M, Potash MJ, Volsky DJ: Human immunodeficiency virus type 1 DNA synthesis, integration, and efficient viral replication in growth-arrest T cells. J Virol 67 (7): 3969-3977, 1993
79. Canivet M, Hoffman AD, Hardy D, Sernatinger J, Levy JA: Replication of HIV-1 in a wide variety of animal cells following phenotypic mixing with murine retroviruses. Virology 178: 543-551, 1990
80. Lusso P, Veronese FDM, Ensoli B, Franchini G, Jemma C, DeRocco SE, Kalyanaraman VS, Gallo RC: Expanded HIV-1 cellular tropism by phenotypic mixing with murine endogenous retroviruses. Science 247: 848-852, 1990
81. Spector DH, Wade E, Wright DA, Koval V, Clak C, Jaquish D, Spector SA: Human immunodeficiency virus pseudotypes with expanded cellular and species tropism. J Virol 64 (5): 2298-2308, 1990
82. Springett GM, Moen RC, Anderson S, Blaese RM, Anderson WF: Infection efficiency of T lymphocytes with amphotropic retroviral vectors is cell cycle dependent. J Virol 63 (9): 3865-3869, 1989
83. Hajihosseini M, Iavachev L, Price J: Evidence that retroviruses integrate into post-replication host DNA. EMBO J 12 (13): 4969-4974, 1993
84. Von Schwedler U, Kornbluth RS, Trono D: The nuclear localization signal of the matrix protein of human immunodeficiency virus type 1 allows the establishment of infection in macrophages and quiescent T lymphocytes. Proc Natl Acad Sci USA 91: 6992-6996, 1994
85. Freed EO, Orenstein JM, Buckler-White AJ, Martin MA: Single amino acid changes in the human immunodificiency virus type 1 matrix protein block virus particle production. J Virol 68 (8): 5311-5320, 1994
86. Heinzinger NK, Bukrinsky MI, Haggerty SA, Ragland AM, Kewalramani V, Lee M, Gendelman HE, Ratner L, Stevenson M, Emerman M: The Vpr protein of human immunodeficiency virus type 1 influences nuclear localization of viral nucleic acids in nondividing host cells. Proc Natl Acad Sci USA 91: 7311-7315, 1994
87. Gallay P, Swingler S, Song J, Bushman F, Trono D: HIV nuclear import is governed by the phosphotyrosine-mediated binding of matrix to the core domain of integrase. Cell 83 (4): 569-576, 1995
88. Deminie CA, Emerman M: Functional exchange of an oncoretrovirus and a lentivirus matrix protein. J Virol 68 (7): 4442-4449, 1994
89. Casse H, Girerd Y, Gazzolo L, Dodon MD: Critical involvement of human T cells leukaemia virus type 1 virions in mediating the viral mitogenic effect. J Gen Virol 75: 1909-1916, 1994
90. Flotte TR, Barraza-Ortiz X, Solow R, Afione SA, Carter BJ, Guggino WB: An improved system for packaging recombinant adeno-associated virus vectors capable of in vivo transduction. Gene Ther 2: 29-37, 1995
91. Philip R, Brunette E, Kilinski L, Murugesh D, McNally MA, Ucar K, Rosenblatt J, Okarma TB, Lebkowski JS: Efficient and sustained gene expression in primary T lymphocytes and primary and cultured tumor cells mediated by adeno-associated virus plasmid DNA complexed to cationic liposomes. Mol Cell Biol 14 (4): 2411-2418, 1994
92. Hettmann T, Cohen A: Identification of a T cell-specific transcriptional enhancer 3′ of the human T cell receptor gamma locus. Mol Immunol 31 (4): 315-322, 1994
93. Rellahan BL, Jensen JP, Weissman AM: Transcriptional regulation of the T cell antigen receptor zeta subunit: Identification of a tissue-restricted promoter. J Exp Med 180 (4): 1529-1534, 1994
94. Greaves DR, Wilson FD, Lang G, Kioussos D: Human CD2 3′-flanking sequences confer high-level. T cell-specific, position-independent gene expression in transgenic mice. Cell 56: 979-986, 1989
95. Buschle M, Cotten M, Kirlappos H, Mechtler K, Schaffner G, Zauner W, Birnstiel ML, Wagner E: Receptor-mediated gene transfer into human T lymphocytes via binding of DNA/CD3 antibody particles to the CD3 T cell receptor complex. Hum Gene Ther 6: 753-761, 1995
96. Brenner MK, Rill DR, Holladay MS, Heslop HE, Moen RC, Buschle M, Krance RA, Santana VM, Anderson WF, Ihle JN: Gene marking to determine whether autologous marrow infusion restores long-term haemopoiesis in cancer patients. Lancet 342: 1134-1137, 1993
97. Schwarzenberger P, Spence SE, Gooya JM, Michiel D, Curiel DT, Ruscetti FW, Keller JR: Targeted gene transfer to human hematopoietic progenitor cell lines through the c-kit receptor. Blood 87 (2): 472-478, 1996
98. Jain RK: Physiological barriers to delivery of monoclonal antibodies and other macromolecules in tumours. Cancer Res 50 (Suppl 3): 814S-819S, 1990
99. Russell SJ: Replicating vectors for cancer therapy: a question of strategy. Semin Cancer Biol 5: 437-443, 1994
100. Black FL: Why did they die? Science 258: 1739-1740, 1992
101. Martuza RL, Malick A, Markert JM, Ruffner KL, Coen DM: Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science 252: 854-856, 1991
102. Erselius JR, Lostes B, Hatzopoulos AK, Mosthaf L, Gruss Cell-type-specific control elements of the lymphotropic papovavirus enhancer. J Virol 64: 1557-1666, 1990
103. Munshi NC, Zhou S, Woody MJ, Morgan DA, Srivastava A: Successful replication of parvovirus B19 in the human megakaryocytic leukemia cell line MB-02. J Virol 67: 562-566, 1993
104. Cornelis JJ, Becquart P, Duponchel N, Salome N, Avalosse BL, Namba M, Rommelaere J: Transormation of human fibroblasts by ionizing radiation, a chemical carcinogen, or simian virus 40 correlates with an increase in susceptibilty to the autonomous parvoviruses H-1 virus and minute virus of mice. J Virol 62: 1679-1686, 1988
105. Russell SJ, Brandenburger A, Flemming CL, Collins MKL, Rommelaere J: Transformation dependent expression of interleukin genes delivered by a recombinant parvovirus. J Virol 66: 2821-2828, 1992
106. Babiss LE, Friedman JM, Darnell Jr JE: Cellular promoters incorporated into the adenovirus genome: Effect of viral DNA replication on endogenous and exogenous gene transcription. J Mol Biol 193: 643-650, 1987
107. Takekoshi M, Maeda-Takekoshi F, Ihara S, Sakuma S, Watanabe Y: Inducible expression of a foreign gene inserted into the human cytomegalovirus genome. J Gen Virol 74: 1649-1652, 1993
108. Mineta T, Rabkin SD, Martuza RL: Treatment of malignant gliomas using ganciclovir-hypersensitive, ribonucleotide reductase-deficient herpes simplex viral mutant. Cancer Res 54 (15): 3963-3966, 1994
109. Yazaki T, Manz HJ, Rabkin SD, Martuza RL: Treatment of human malignant meningiomas by G207. a replication-competent multimutated herpes simplex virus 1. Cancer Res 55 (21): 4752-4756, 1995
110. Martuza RT, Rabkin SD, Yazaki T, Hunter WD, Martuza RL: Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nature Med 1 (9): 938-943, 1995